Elcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx’s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. 

The Elcelyx lead proprietary product candidate, a delayed-release metformin formulation for type 2 diabetes has completed Phase 2b development and is a potential blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic medication market.

Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. 

Elcelyx is headquartered in San Diego, California.